BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

115 related articles for article (PubMed ID: 35358259)

  • 1. Clinical utility of comprehensive genomic profiling in Japan: Result of PROFILE-F study.
    Aoyagi Y; Kano Y; Tohyama K; Matsudera S; Kumaki Y; Takahashi K; Mitsumura T; Harada Y; Sato A; Nakamura H; Sueoka E; Aragane N; Kimura K; Onishi I; Takemoto A; Akahoshi K; Ono H; Ishikawa T; Tokunaga M; Nakagawa T; Oshima N; Nakamura R; Takagi M; Asakage T; Uetake H; Tanabe M; Miyake S; Kinugasa Y; Ikeda S
    PLoS One; 2022; 17(3):e0266112. PubMed ID: 35358259
    [TBL] [Abstract][Full Text] [Related]  

  • 2. [Clinical Utility of Comprehensive Genome Profiling Using FoundationOne CDx in Japanese Population(PROFILE-F Study)].
    Kumaki Y; Takahashi K; Mitsumura T; Yokobori J; Takamine E; Ishibashi E; Sakashita H; Ishikawa T; Ono H; Ban D; Kudo A; Oshima N; Nakagawa T; Kimura K; Kubota K; Onishi I; Tanabe M; Uetake H; Miyake S; Ikeda S
    Gan To Kagaku Ryoho; 2019 Nov; 46(11):1715-1719. PubMed ID: 31748480
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Clinical Application of the FoundationOne CDx Assay to Therapeutic Decision-Making for Patients with Advanced Solid Tumors.
    Takeda M; Takahama T; Sakai K; Shimizu S; Watanabe S; Kawakami H; Tanaka K; Sato C; Hayashi H; Nonagase Y; Yonesaka K; Takegawa N; Okuno T; Yoshida T; Fumita S; Suzuki S; Haratani K; Saigoh K; Ito A; Mitsudomi T; Handa H; Fukuoka K; Nakagawa K; Nishio K
    Oncologist; 2021 Apr; 26(4):e588-e596. PubMed ID: 33325566
    [TBL] [Abstract][Full Text] [Related]  

  • 4. First-Line Genomic Profiling in Previously Untreated Advanced Solid Tumors for Identification of Targeted Therapy Opportunities.
    Matsubara J; Mukai K; Kondo T; Yoshioka M; Kage H; Oda K; Kudo R; Ikeda S; Ebi H; Muro K; Hayashi R; Tokudome N; Yamamoto N; Muto M
    JAMA Netw Open; 2023 Jul; 6(7):e2323336. PubMed ID: 37459099
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Comprehensive molecular profiling broadens treatment options for breast cancer patients.
    Kawaji H; Kubo M; Yamashita N; Yamamoto H; Kai M; Kajihara A; Yamada M; Kurata K; Kaneshiro K; Harada Y; Hayashi S; Shimazaki A; Mori H; Akiyoshi S; Oki E; Oda Y; Baba E; Mori M; Nakamura M
    Cancer Med; 2021 Jan; 10(2):529-539. PubMed ID: 33274848
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Clinical impact of a cancer genomic profiling test using an in-house comprehensive targeted sequencing system.
    Hayashi H; Tanishima S; Fujii K; Mori R; Okada C; Yanagita E; Shibata Y; Matsuoka R; Amano T; Yamada T; Yabe I; Kinoshita I; Komatsu Y; Dosaka-Akita H; Nishihara H
    Cancer Sci; 2020 Oct; 111(10):3926-3937. PubMed ID: 32772458
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Clinical significance of comprehensive genomic profiling tests covered by public insurance in patients with advanced solid cancers in Hokkaido, Japan.
    Kikuchi J; Ohhara Y; Takada K; Tanabe H; Hatanaka K; Amano T; C Hatanaka K; Hatanaka Y; Mitamura T; Kato M; Shibata Y; Yabe I; Endoh A; Komatsu Y; Matsuno Y; Sugiyama M; Manabe A; Sakurai A; Takahashi M; Naruse H; Torimoto Y; Dosaka-Akita H; Kinoshita I
    Jpn J Clin Oncol; 2021 Apr; 51(5):753-761. PubMed ID: 33532831
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Molecular Profiling and Targeted Therapy in Cholangiocarcinoma: An Observational, Retrospective Multicenter Study.
    Garcia-Pardo M; Ortega L; Fernández-Aceñero MJ; García Alfonso P; Martín M; Muñoz AJ
    J Gastrointest Cancer; 2021 Jun; 52(2):814-818. PubMed ID: 33683644
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Clinical genomic profiling to identify actionable alterations for investigational therapies in patients with diverse sarcomas.
    Groisberg R; Hong DS; Holla V; Janku F; Piha-Paul S; Ravi V; Benjamin R; Kumar Patel S; Somaiah N; Conley A; Ali SM; Schrock AB; Ross JS; Stephens PJ; Miller VA; Sen S; Herzog C; Meric-Bernstam F; Subbiah V
    Oncotarget; 2017 Jun; 8(24):39254-39267. PubMed ID: 28424409
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Clinical and Diagnostic Utility of Genomic Profiling for Digestive Cancers: Real-World Evidence from Japan.
    Ishikawa M; Nakamura K; Kawano R; Hayashi H; Ikeda T; Saito M; Niida Y; Sasaki J; Okuda H; Ishihara S; Yamaguchi M; Shimada H; Isobe T; Yuza Y; Yoshimura A; Kuroda H; Yukisawa S; Aoki T; Takeshita K; Ueno S; Nakazawa J; Sunakawa Y; Nohara S; Okada C; Nishimiya K; Tanishima S; Nishihara H
    Cancers (Basel); 2024 Apr; 16(8):. PubMed ID: 38672586
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Clinical genomic profiling to identify actionable alterations for very early relapsed triple-negative breast cancer patients in the Chinese population.
    Wang L; Zhai Q; Lu Q; Lee K; Zheng Q; Hong R; Wang S
    Ann Med; 2021 Dec; 53(1):1358-1369. PubMed ID: 34396843
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The spectrum of genetic variants in hereditary pancreatic cancer includes Fanconi anemia genes.
    Slavin TP; Neuhausen SL; Nehoray B; Niell-Swiller M; Solomon I; Rybak C; Blazer K; Adamson A; Yang K; Sand S; Guerrero-Llamas N; Castillo D; Herzog J; Wu X; Tao S; Raja S; Chung V; Singh G; Nadesan S; Brown S; Cruz-Correa M; Petersen GM; Weitzel J;
    Fam Cancer; 2018 Apr; 17(2):235-245. PubMed ID: 28687971
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Circulating Tumor DNA-Based Testing and Actionable Findings in Patients with Advanced and Metastatic Pancreatic Adenocarcinoma.
    Botrus G; Kosirorek H; Sonbol MB; Kusne Y; Uson Junior PLS; Borad MJ; Ahn DH; Kasi PM; Drusbosky LM; Dada H; Surapaneni PK; Starr J; Ritter A; McMillan J; Wylie N; Mody K; Bekaii-Saab TS
    Oncologist; 2021 Jul; 26(7):569-578. PubMed ID: 33555095
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Molecular profiling of advanced solid tumors and patient outcomes with genotype-matched clinical trials: the Princess Margaret IMPACT/COMPACT trial.
    Stockley TL; Oza AM; Berman HK; Leighl NB; Knox JJ; Shepherd FA; Chen EX; Krzyzanowska MK; Dhani N; Joshua AM; Tsao MS; Serra S; Clarke B; Roehrl MH; Zhang T; Sukhai MA; Califaretti N; Trinkaus M; Shaw P; van der Kwast T; Wang L; Virtanen C; Kim RH; Razak AR; Hansen AR; Yu C; Pugh TJ; Kamel-Reid S; Siu LL; Bedard PL
    Genome Med; 2016 Oct; 8(1):109. PubMed ID: 27782854
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Genomic Alterations in Circulating Tumor DNA from Diverse Cancer Patients Identified by Next-Generation Sequencing.
    Schwaederle M; Chattopadhyay R; Kato S; Fanta PT; Banks KC; Choi IS; Piccioni DE; Ikeda S; Talasaz A; Lanman RB; Bazhenova L; Kurzrock R
    Cancer Res; 2017 Oct; 77(19):5419-5427. PubMed ID: 28807936
    [TBL] [Abstract][Full Text] [Related]  

  • 16. A Pilot Study Analyzing the Clinical Utility of Comprehensive Genomic Profiling Using Plasma Cell-Free DNA for Solid Tumor Patients in Japan (PROFILE Study).
    Matsudera S; Kano Y; Aoyagi Y; Tohyama K; Takahashi K; Kumaki Y; Mitsumura T; Kimura K; Onishi I; Takemoto A; Ban D; Ono H; Kudo A; Oshima N; Ogino K; Watanabe S; Tani Y; Yamaguchi T; Nakajima M; Morita S; Yamaguchi S; Takagi M; Ishikawa T; Nakagawa T; Okamoto K; Uetake H; Tanabe M; Miyake S; Tsuchioka T; Kojima K; Ikeda S
    Ann Surg Oncol; 2021 Dec; 28(13):8497-8505. PubMed ID: 33778906
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Clinical and analytical validation of FoundationOne®CDx, a comprehensive genomic profiling assay for solid tumors.
    Milbury CA; Creeden J; Yip WK; Smith DL; Pattani V; Maxwell K; Sawchyn B; Gjoerup O; Meng W; Skoletsky J; Concepcion AD; Tang Y; Bai X; Dewal N; Ma P; Bailey ST; Thornton J; Pavlick DC; Frampton GM; Lieber D; White J; Burns C; Vietz C
    PLoS One; 2022; 17(3):e0264138. PubMed ID: 35294956
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Discovery of actionable genetic alterations with targeted panel sequencing in children with relapsed or refractory solid tumors.
    Lee JW; Kim NKD; Lee SH; Cho HW; Ma Y; Ju HY; Yoo KH; Sung KW; Koo HH; Park WY
    PLoS One; 2019; 14(11):e0224227. PubMed ID: 31747416
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Clinical Significance of Multi-Cancer Genome Profiling: Data from a Single Hospital in Japan.
    Aoyama R; Nishikubo H; Kawabata K; Kanei S; Yamamoto Y; Nishimura S; Yashiro M
    Cancer Genomics Proteomics; 2024; 21(1):79-87. PubMed ID: 38151295
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Characterization of Blood-Based Molecular Profiling in Pancreatic Adenocarcinoma.
    Chung C; Galvin R; Achenbach E; Dziadkowiec O; Sen S
    Oncology (Williston Park); 2021 Dec; 35(12):794-803. PubMed ID: 35089001
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.